Prime Medicine Inc [NASDAQ: PRME] closed the trading session at $1.62.
The stocks have a year to date performance of -44.69 percent and weekly performance of 4.19 percent. The stock has been moved at -46.35 percent over the last six months. The stock has performed 1.57 percent around the most recent 30 days and changed -8.24 percent over the most recent 3-months.
If compared to the average trading volume of 1.92M shares, PRME reached to a volume of 6167988 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Prime Medicine Inc [PRME]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PRME shares is $7.69 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PRME stock is a recommendation set at 1.73. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Prime Medicine Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 27, 2025. The new note on the price target was released on May 20, 2025, representing the official price target for Prime Medicine Inc stock.
The Average True Range (ATR) for Prime Medicine Inc is set at 0.17, with the Price to Sales ratio for PRME stock in the period of the last 12 months amounting to 55.07. The Price to Book ratio for the last quarter was 1.98, with the Price to Cash per share for the same quarter was set at 1.10.
PRME stock trade performance evaluation
Prime Medicine Inc [PRME] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.19. With this latest performance, PRME shares gained by 1.57% in over the last four-week period, additionally sinking by -46.35% over the last 6 months – not to mention a drop of -79.56% in the past year of trading.
#####
Prime Medicine Inc [PRME]: An insightful look at the core fundamentals
Prime Medicine Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.78 and a Current Ratio set at 4.78.
Earnings per share (EPS) analysis for Prime Medicine Inc [PRME] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRME. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Prime Medicine Inc go to 18.30%.
Prime Medicine Inc [PRME]: Institutional Ownership
The top three institutional holders of PRME stocks are: ALPHABET INC. with ownership of 15.06 million shares, which is approximately 12.6375%. ARK INVESTMENT MANAGEMENT LLC, holding 6.13 million shares of the stock with an approximate value of $$31.49 million in PRME stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $$31.25 million in PRME stock with ownership which is approximately 5.1002%.
